Management strategies for idiopathic intracranial hypertension

Margaret M. Reynolds, Mary Claire McGlynn, Mohamed Al-Ameri, Nagham Al-Zubidi

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Idiopathic intracranial hypertension (IIH) is a debilitating medical condition with an unknown cause. Its a diagnosis of exclusion and alternative etiologies of raised increased intracranial pressure should be investigated. Unfortunately, to date, there have been no clinical trials to guide treatment of IIH. Current treatment consists of medical and surgical therapy. Medical therapy with weight loss and diuretics, for example, acetazolamide, is typically the mainstay of treatment for IIH. Patients who fail medical therapy due to intolerance, non-compliance, or patients with fulminant IIH may require further surgical treatment. The decision of which surgical procedure is optimal depends on the patient's predominant symptoms (refractory headache vs risk of vision loss), the availability of local oculoplastic/neurosurgical expertise (optic nerve sheath fenestration or shunting) and patient preference. In this review the authors provide an overview of the different treatment options and outline the latest advances and strategies in the treatment of IIH.

Original languageEnglish
Pages (from-to)331-340
Number of pages10
JournalExpert Review of Ophthalmology
Issue number4
StatePublished - Aug 2014


  • acetazolamide
  • cerebrospinal fluid shunting
  • idiopathic intracranial hypertension
  • optic nerve sheath fenestration
  • papilledema
  • pseudotumor cerebri
  • topiramate
  • transverse venous stenting


Dive into the research topics of 'Management strategies for idiopathic intracranial hypertension'. Together they form a unique fingerprint.

Cite this